Jason Mast is a general assignment reporter at STAT focused on the science behind new medicines and the systems and people that decide whether that science ever reaches patients. You can reach Jason ...

It seems the return of the V8-powered Mopar muscle car is certainly underway. Stellantis reportedly just allocated a whopping $10-billion investment into new US-based manufacturing, largely to support ...

"I don't like the attention at all," said Shep, as his family and friends call him, who gets a lot of it at school. "It just annoys me, that every day I'm asked, 'Hey, why do you need a wheelchair?' ...

MISSISSAUGA, ON, Oct. 2, 2025 /PRNewswire/ - Kye Pharmaceuticals ("Kye") announced today that Health Canada has approved AGAMREE® (vamorolone) for the treatment of Duchenne Muscular Dystrophy (DMD) in ...

Shepherd Riddle, 11, has Duchenne Muscular Dystrophy, which weakens muscles, the heart and lungs over time. New COVID variant ‘Stratus’ on the rise, what are the symptoms? 'Come-to-Jesus meeting’: ...

Muscular dystrophies are a group of inherited disorders that cause progressive breakdown of muscle tissue. Two of the most common types are Duchenne muscular dystrophy (DMD) and Becker muscular ...

People with Duchenne muscular dystrophy have a shorter-than-average life expectancy due to changes in muscles that affect breathing, heart activity, and other functions. However, treatment advances ...

People with Duchenne muscular dystrophy (DMD) frequently live well into adulthood. Advances in treatment have significantly increased the life expectancy for this condition. The median life expectancy ...

There is no cure for DMD, but treatments can slow the progression of the disease and help improve quality of life. Duchenne muscular dystrophy (DMD) is a chronic condition that causes a gradual loss ...

Jillian Kubala, MS, is a registered dietitian based in Westhampton, NY. Jillian uses a unique and personalized approach to help her clients achieve optimal wellness through nutrition and lifestyle ...

Avidity Biosciences, Inc. (NASDAQ:RNA) on Wednesday shared new data from participants treated continuously with del-zota for one year in the EXPLORE44 and EXPLORE44-OLE trials for Duchenne muscular ...